Fig 1.
Cumulative incidence of cancer among female (A) and male (B) smoking cessation treatment patients versus matched controls.
The follow-up period begins the day after enrolment in smoking cessation treatment (treatment cohort) or survey completion (control cohort) in 2011/2012 and ends December 31, 2017 (or date of death if it occurred first). Shaded areas indicate the 95% CI. Number of individuals at risk at each time point is presented below the x axis.
Table 1.
Estimated risk of chronic disease among treated and matched control groups at 5 years post index, accounting for death as a competing event.
Fig 2.
Cumulative incidence of COPD among female (A) and male (B) smoking cessation treatment patients versus matched controls.
The follow-up period begins the day after enrolment in smoking cessation treatment (treatment cohort) or survey completion (control cohort) in 2011/2012 and ends December 31, 2017 (or date of death if it occurred first). Shaded areas indicate the 95% CI. Number of individuals at risk at each time point is presented below the x axis.
Fig 3.
Cumulative incidence of diabetes among female (A) and male (B) smoking cessation treatment patients versus matched controls.
The follow-up period begins the day after enrolment in smoking cessation treatment (treatment cohort) or survey completion (control cohort) in 2011/2012 and ends December 31, 2017 (or date of death if it occurred first). Shaded areas indicate the 95% CI. Number of individuals at risk at each time point is presented below the x axis.
Fig 4.
Cumulative incidence of hypertension among female (A) and male (B) smoking cessation treatment patients versus matched controls.
The follow-up period begins the day after enrolment in smoking cessation treatment (treatment cohort) or survey completion (control cohort) in 2011/2012 and ends December 31, 2017 (or date of death if it occurred first). Shaded areas indicate the 95% CI. Number of individuals at risk at each time point is presented below the x axis.
Fig 5.
Cumulative incidence of major cardiovascular events among female (A) and male (B) smoking cessation treatment patients versus matched controls.
The follow-up period begins the day after enrolment in smoking cessation treatment (treatment cohort) or survey completion (control cohort) in 2011/2012 and ends December 31, 2017 (or date of death if it occurred first). Shaded areas indicate the 95% CI. Number of individuals at risk at each time point is presented below the x axis.